Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 Dec 1.

Published in final edited form as: Neuropathol Appl Neurobiol. 2020 Sep 24;46(7):707–721. doi: 10.1111/nan.12659

Table 1.

Patient Demographics

	LBD-AD N=30	LBD+AD N=19	AD N=30
Clinical Characteristics
Clinical Phenotype	DLB: 6 PDD: 24	DLB: 11 PDD: 8^†	AD: 30
Sex, count male (%)	23 (77)	14 (74)	14 (47)^*
Age at Death^a	77.3 (8.7)	78.6 (6.2)	74.4 (10.7)
Disease Duration^a	15.8 (7.3)	9.1 (6.6)^†	11.0 (4.8)^*^†
Neuropathology
Brain Weight^b	1325 (134)	N=18, 1331 (134)	1081 (136)^*^†^‡
Post Mortem Interval^c	13.7 (11.5)	N=18, 16.6 (8.6)	10.7 (5.9)
McKeith Stages^d
Brainstem	2 (7)	0 (0)	0 (0)
Limbic	8 (27)	2 (11)	0 (0)
Neocortical	20 (67)	17 (89)	0 (0)
AD Neuropathologic change^e
No	11 (37)	0 (0)	0 (0)
Low	19 (63)	0 (0)	0 (0)
Intermediate	0 (0)	11 (58)	3 (10)
High	0 (0)	8 (27)	27 (30)^*^‡
Other Co-Pathologies^f
PART	3 (10)	0 (0)	0 (0)
TDP-43	7 (23)	8 (42)^†	17(57)^*
ARTAG	N=23, 8 (35)	N=17, 12 (71)	N=23, 17(74)^*

^a:

years (SD).

^b:

grams (SD).

^c:

hours (SD).

^d:

count (%) derived from McKeith et al. 2005.

^e:

count (%) from Montine et al. 2011.

^f:

count (%) Unless specified all values are derived from the whole cohort.

Abbreviations: PART: primary age related tauopathy, TDP-43: TAR DNA binding progrein-43. ARTAG: age related tau astrogliopathy

^*

p<0.05 across groups

^†

p<0.05 compared to LBD-AD

^‡

p<0.05 compared to LBD+AD